Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesValidation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03
Journal of Clinical Oncology, 08/14/09
Le QT et al. - In a study to validate lysyl oxidase (LOX) as a marker for metastasis in an independent head and neck cancer (HNC) pt group enrolled onto a prospective trial, it was determined that automated quantitative analysis (AQUA) LOX expression was strongly associated with increased metastasis, progression, and death in RTOG 90-03 pts. This study validates that LOX is a marker for metastasis and survival in HNC.
Methods- Traditional immunohistochemical (IHC) staining and AQUA for LOX expression were performed in 66 HNC pts.
- AQUA staining was also done for LOX in 306 of 1113 pts treated on a phase III trial comparing 4 radiation fractionation schedules in locally advanced HNC (RTOG 90-03).
- Pretreatment characteristics and outcome were similar between pts with and without LOX assessment.
- AQUA LOX expression was correlated with time to metastasis (TTM), time to progression (TTP), and overall survival (OS).
- LOX expression from both staining methods predicted for TTM in the first 66 pts.
- Multivariate analysis, controlling for significant parameters including nodal stage and performance status, revealed tumor LOX expression, as a continuous variable, was an independent predictor for TTM, TTP, and OS.
- This translates into a 259% increase in metastatic risk for a pt at the 75th percentile of LOX vs 1 at the 25th percentile.
Related Articles
Basaloid squamous cell carcinomas of the head and neck
Bulletin du Cancer, 10/19/09
Relevance Score: 94%
HER2 expression predicts improved survival in patients with cervical node–positive head and neck squamous cell carcinoma
Otolaryngology Head and Neck Surgery, 10/13/09
Relevance Score: 94%
Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model
BMC: Journal of Biomedical Science, 11/17/09
Relevance Score: 93%
Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas
European Journal of Surgical Oncology, 11/16/09
Relevance Score: 93%
Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009
The Lancet Oncology, 11/02/09
Relevance Score: 93%
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Expression of p16 in benign and malignant cystic squamous lesions of the neck
Human Pathology, 12/19/09
Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas
Human Pathology, 12/19/09
Overexpression of Kif2a promotes the progression and metastasis of squamous cell carcinoma of the oral tongue
Oral Oncology , 12/19/09
Sponsor
Article Search
Sponsor
Sponsor